Hyperthermia and the need to monitor temperature

Extensive biologic research has shown that adjuvant thermal therapy, i.e. heating tumors to 40–43°C, is a promising approach to increase the efficacy of existing radio- and chemotherapy protocols. The fact that in clinical trials, hyperthermia has shown not to increase toxicity is a major drive to invest in developing innovative devices and applicators to deliver thermal therapies. Moreover, the recent demonstrated ability of hyperthermia to decrease the repair of DNA double strand breaks provides a gateway to new treatments strategies involving hyperthermia and in combination with temperature sensitive drug carriers hyperthermia can be used for triggered local drug delivery.